Intended for Healthcare Professionals

Login / Register

Logout
uk

Adverse event reporting can be found at the bottom of the page

 ViiV exchange  ViiV exchange

United Kingdom

UK

  • Medicines +

    ViiV Healthcare remains committed to developing and investing in new medicines and innovations that aim to improve the treatment success and quality of life of all people living with HIV

    See medicines

    • APRETUDE ▼ (cabotegravir) Prescribing information
    • DOVATO (dolutegravir/lamivudine) Prescribing information
    • Vocabria ▼ (Cabotegravir) + Rekambys ▼ (Rilpivirine) Prescribing Information
    • Rukobia ▼ (Fostemsavir) Prescribing Information
    • JULUCA (dolutegravir/rilpivirine) Prescribing information
    • TRIUMEQ (dolutegravir/ abacavir/ lamivudine) Prescribing information
    • TRIUMEQ (dolutegravir/ abacavir/ lamivudine) Dispersible Tablets Prescribing information
    • TIVICAY (dolutegravir) Prescribing information
    • TIVICAY (dolutegravir) 5 mg dispersible tablets Prescribing information
  • Optimising Care +
    • HIV Continuum
  • Resources
  • Contact Us
uk
Login / Register

Logout
search
OPEN
CLOSE
  • Medicines +

    ViiV Healthcare remains committed to developing and investing in new medicines and innovations that aim to improve the treatment success and quality of life of all people living with HIV

    See medicines

    • APRETUDE ▼ (cabotegravir) Prescribing information
    • DOVATO (dolutegravir/lamivudine) Prescribing information
    • Vocabria ▼ (Cabotegravir) + Rekambys ▼ (Rilpivirine) Prescribing Information
    • Rukobia ▼ (Fostemsavir) Prescribing Information
    • JULUCA (dolutegravir/rilpivirine) Prescribing information
    • TRIUMEQ (dolutegravir/ abacavir/ lamivudine) Prescribing information
    • TRIUMEQ (dolutegravir/ abacavir/ lamivudine) Dispersible Tablets Prescribing information
    • TIVICAY (dolutegravir) Prescribing information
    • TIVICAY (dolutegravir) 5 mg dispersible tablets Prescribing information
  • Optimising Care +
    • HIV Continuum
  • Resources
  • Contact Us
uk
Login / Register

Logout

Logout
  Login Register
Vocabria and Rekambys Logo

Explore

  • Overview

  • Efficacy

    +
    • SOLAR introduction
    • SOLAR results
  • Safety & 
    Tolerability

    +
    • SOLAR safety and tolerability
    • Overall safety profile
    • Important prescribing considerations and drug-drug interactions
  • Dosing & Drug
    Interactions

  • People living with
    HIV Experiences

    +
    • Challenges with Daily Oral Therapy
    • Patient Preference
  • Implementation

    +
    • CARISEL Study
    • Implementation Case Studies
  • Real-World
    Evidence

    +
    • Opera Study
    • Carlos Study
  • Resources &
    Downloads

    +
    • Healthcare Team Resources
    • Patient Resources
    • Nurse Network
    • Media Library
Adverse event reporting can be found at the bottom of the page

KEY SOLAR PRO DATA

Vocabria and Rekambys SOLAR PRO data
Vocabria and Rekambys SOLAR PRO data

< Back to resources

PM-GB-CBR-WCNT-230009 | December 2023

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.

ViiV Exchange logo
United Kingdom

ViiV Healthcare
79 New Oxford Street
London
United Kingdom
WC1A 1DG

Tel: +44 20 8047 5000

  • Contact us
  • Cookie policy
  • Privacy notice
  • Terms of use
  • About Us
  • ViiV Healthcare
  • LiVLife

 

Copyright © 2020 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare UK Limited. Registered in England and Wales No. 06990358.

PM-GB-HVX-WCNT-230004 | August 2024

ViiV Healthcare logo

Are you a UK Healthcare Professional?

This site is intended for UK Healthcare Professionals. By entering this site, you are confirming that you are a UK Healthcare Professional. This site may contain promotional information.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline via the GSK Reporting Tool or on 0800 221441.

PM-GB-HVX-WCNT-230004 | July 2024

No, I am not a Healthcare Professional Yes, I am

Select Country & Language

  • UK

    English

    • Australia

      English

    • Belgium

      English

    • Canada

      English Français

    • España

      Español

    • France

      Français

    • Germany

      Deutsch

    • Italy

      Italiano

    • Japan

      日本人

    • Netherlands

      English

    • Portugal

      Portuguese

    • Switzerland

      English

    • United States

      English

    YOU ARE LEAVING THE SITE

    You are about to leave a ViiV Healthcare website. By clicking this link, you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.

    Cancel Accept

    We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences and advertising cookies help us share relevant content. Cookie Policy

    Show detail Show less
    • Performance cookies

      Collect information about your use of our website, e.g. page visits or error messages. This information is aggregated and anonymised and used to improve our website. If you don’t allow these cookies, we won’t know when you have visited our website and won’t be able to monitor its performance

    • Functional cookies

      Allow our websites to remember your user name, language preference, or geographic region. This information is used to provide a personalised experience and to make the website easier to use. If you don’t allow these cookies, then some or all features may not function

    • Advertising cookies

      Allow us to display advertising we think is relevant to you. We build profiles based on your browsing history, which we share with our advertising partners to show you relevant advertisements on other sites. If you don’t allow these cookies you will still receive advertising, but it will be less relevant